WallStSmart

Akso Health Group ADR (AHG)vsHenry Schein Inc (HSIC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 98238% more annual revenue ($13.60B vs $13.83M). HSIC leads profitability with a 3.0% profit margin vs -135.0%. HSIC earns a higher WallStSmart Score of 56/100 (C).

AHG

Avoid

15

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.3Quality: 9.0
Piotroski: 5/9Altman Z: 12.00

HSIC

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHGUndervalued (+10.2%)

Margin of Safety

+10.2%

Fair Value

$1.57

Current Price

$0.75

$0.82 discount

UndervaluedFair: $1.57Overvalued
HSICUndervalued (+47.6%)

Margin of Safety

+47.6%

Fair Value

$156.00

Current Price

$86.37

$69.63 discount

UndervaluedFair: $156.00Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
12.0010/10

Safe zone — low bankruptcy risk

HSIC0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AHG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$634.05M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-89.4%2/10

ROE of -89.4% — below average capital efficiency

Revenue GrowthGrowth
-12.9%2/10

Revenue declined 12.9%

HSIC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.213/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.

Bull Case : HSIC

HSIC has a balanced fundamental profile.

Bear Case : AHG

The primary concerns for AHG are EPS Growth, Market Cap, Return on Equity.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, Profit Margin, Debt/Equity. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

AHG profiles as a turnaround stock while HSIC is a value play — different risk/reward profiles.

HSIC carries more volatility with a beta of 0.81 — expect wider price swings.

HSIC is growing revenue faster at 6.7% — sustainability is the question.

HSIC generates stronger free cash flow (196M), providing more financial flexibility.

Bottom Line

HSIC scores higher overall (56/100 vs 15/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, dedicated to providing innovative medical solutions and comprehensive patient care services. With a strong emphasis on advanced health technologies, the company is strategically positioned in the telehealth and personalized medicine markets, supported by a robust research and development framework. As it navigates the rapidly evolving healthcare landscape, Akso Health Group presents an attractive investment opportunity for institutional investors seeking to capitalize on transformative trends within the industry.

Visit Website →

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?